BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Fulvestrant: trial readouts and FDA decisions
6 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 7 readout(s) in the last 180 days and 1 FDA event(s) in the last 12 months. Sponsors: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Novartis Pharmaceuticals, InventisBio Co., Ltd, Phoenix Molecular Designs, Pfizer, Hoffmann-La Roche, AstraZeneca, Olema Oncology, Inc.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-30 est. | P3 | InventisBio Co., Ltd | NCT06954961 A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer | Breast Cancer | recruiting | 640 |
| 2026-12 est. | P1/P2 | Phoenix Molecular Designs | NCT04115306 Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer | Metastatic Breast Cancer | active not recruiting | 61 |
| 2026-12 est. | P1/P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06202261 A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer | Metastatic Breast Cancer; Recurrent Breast Cancer; Advanced Malignancies | recruiting | 154 |
| 2026-12-31 est. | P2 | Pfizer PFE | NCT04553133 PF-07104091 as a Single Agent and in Combination Therapy | Small Cell Lung Cancer; Ovarian Cancer; Breast Cancer | active not recruiting | 157 |
| 2027-01-28 est. | P3 | Novartis Pharmaceuticals NVS | NCT05038735 Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatm | Breast Cancer | active not recruiting | 210 |
| 2027-01-29 est. | P2 | Novartis Pharmaceuticals NVS | NCT04544189 Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women Wit | Breast Neoplasms | active not recruiting | 69 |
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-04-13 | Complete response letter | complete response | Eagle Pharmaceuticals, Inc. EXP | Fulvestrant | CRL 2026-04-13: Eagle Pharmaceuticals, Inc. NDA 220045 (Fulvestrant Injection) |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-13 est. | P3 | Hoffmann-La Roche | NCT05646862 A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negati | Breast Cancer | recruiting | 420 |
| 2026-10-31 est. | P3 | AstraZeneca AZN | NCT06635447 Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients | Breast Cancer | active not recruiting | 293 |
| 2026-10-31 est. | P3 | Olema Oncology, Inc. OLMA | NCT06016738 OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer; HER2 Neg | active not recruiting | 510 |
| 2026-10 est. | P3 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT06929325 Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibi | HR+/HER2- Advanced/Metastatic Breast Cancer | not yet recruiting | 312 |
| 2026-08 est. | P1/P2 | Treadwell Therapeutics, Inc | NCT05251714 CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer | Advanced Solid Tumor; Breast Cancer | active not recruiting | 44 |
| 2026-06-30 est. | P3 | Celcuity Inc CELC | NCT05501886 Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer ( | Breast Cancer | active not recruiting | 701 |
| 2026-06 est. | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06702618 Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer | Breast Cancer | active not recruiting | 33 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.